The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats.
The present study sought to determine whether the combination of late preconditioning (PC) with postconditioning enhances the reduction in infarct size. Chronically instrumented rats were assigned to a 45-min (subset 1) or 60-min (subset 2) coronary occlusion followed by 24 h of reperfusion. In each subset, rats received no further intervention (control) or were preconditioned 24 h before occlusion (PC), postconditioned at the onset of reperfusion following occlusion, or preconditioned and postconditioned without (PC + postconditioning) or with the COX-2 inhibitor celecoxib (3 mg/kg ip; PC + postconditioning + celecoxib) 10 min before postconditioning. Myocardial cyclooxygenase-2 (COX-2) protein expression and COX-2 activity (assessed as myocardial levels of PGE(2)) were measured 6 min after reperfusion in an additional five groups (control, PC, postconditioning, PC + postconditioning, and PC + postconditioning + celecoxib) subjected to a 45-min occlusion. PC alone reduced infarct size after a 45-min occlusion but not after a 60-min occlusion. Postconditioning alone did not reduce infarct size in either setting. However, the combination of late PC and postconditioning resulted in a robust infarct-sparing effect in both settings, suggesting additive cardioprotection. Celecoxib completely abrogated the infarct-sparing effect of the combined interventions in both settings. Late PC increased COX-2 protein expression and PGE(2) content. PGE(2) content (but not COX-2 protein) was further increased by the combination of both interventions, suggesting that postconditioning increases the activity of COX-2 induced by late PC. In conclusion, the combination of late PC and postconditioning produces additive protection, likely due to a postconditioning-induced enhancement of COX-2 activity.
Sato
Hiroshi
H
Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky 40202, USA.
Bolli
Roberto
R
Rokosh
Gregg D
GD
Bi
Qiuli
Q
Dai
Shujing
S
Shirk
Gregg
G
Tang
Xian-Liang
XL
D000818:Animals; D000068579:Celecoxib; D003243:Consciousness; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015232:Dinoprostone / Q000378:metabolism; D004195:Disease Models, Animal; D019194:Ischemic Preconditioning / Q000379:methods; D008297:Male; D009203:Myocardial Infarction / Q000201:enzymology / Q000378:metabolism / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000201:enzymology / Q000378:metabolism / Q000517:prevention & control*; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011916:Rats, Inbred F344; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D015854:Up-Regulation
D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; C489691:Ptgs2 protein, rat; D000068579:Celecoxib; D015232:Dinoprostone
Cardiovasc Res. 2004 Oct 1;64(1):61-71
15364614
J Am Coll Cardiol. 2003 Apr 2;41(7):1183-94
12679220
Circulation. 2005 Jan 18;111(2):194-7
15642769
Circ Res. 1997 Dec;81(6):1094-107
9400391
Cardiovasc Res. 2006 May 1;70(2):315-24
16443207
Am J Physiol Heart Circ Physiol. 2006 Nov;291(5):H2308-17
16815986
J Am Coll Cardiol. 2003 Apr 2;41(7):1195-7
12679221
Basic Res Cardiol. 2005 Jan;100(1):57-63
15614590
Anesthesiology. 2004 Mar;100(3):547-54
15108967
J Am Coll Cardiol. 2004 Sep 1;44(5):1103-10
15337225
Circulation. 1998 Aug 4;98(5):441-9
9714095
Basic Res Cardiol. 2005 Jul;100(4):295-310
15793629
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10197-202
10963682
Life Sci. 2006 Apr 25;78(22):2543-9
16325209
Trends Cardiovasc Med. 2005 Feb;15(2):69-75
15885573
Basic Res Cardiol. 1996 Jan-Feb;91(1):1-4
8660246
Life Sci. 2004 May 28;75(2):129-40
15120566
Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1618-26
15937101
Cardiovasc Res. 2002 Aug 15;55(3):495-505
12160946
Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H19-27
16963615
Circ Res. 2004 Aug 6;95(3):230-2
15242972
Expert Rev Cardiovasc Ther. 2005 Nov;3(6):1035-45
16292995
Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H579-88
12860564
Basic Res Cardiol. 2000 Dec;95(6):479-84
11192369
Basic Res Cardiol. 2006 Nov;101(6):502-7
16830072
Cardiovasc Res. 2005 Jul 1;67(1):124-33
15949476
Am J Physiol Heart Circ Physiol. 2006 May;290(5):H1960-8
16339820
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7
8265610
Anesthesiology. 2004 Mar;100(3):525-31
15108964
Anesthesiology. 2005 Jan;102(1):102-9
15618793
Circ Res. 2000 Nov 24;87(11):972-83
11090541
Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H971-6
15358610
Am J Physiol Heart Circ Physiol. 2002 Nov;283(5):H1943-57
12384473
Trends Cardiovasc Med. 1992 Sep-Dec;2(5):170-6
21239250
Basic Res Cardiol. 2006 Jul;101(4):354-6
16568250
Cardiovasc Res. 2003 Jun 1;58(3):582-8
12798431
Circ Res. 2003 Apr 18;92(7):741-8
12702642
Circ Res. 2002 Mar 22;90(5):602-8
11909825
J Mol Cell Cardiol. 2003 May;35(5):525-37
12738234
J Am Coll Cardiol. 2005 May 17;45(10):1707-15
15893191
Circ Res. 2002 Aug 9;91(3):240-6
12169650
Ann Thorac Surg. 2004 Sep;78(3):961-9; discussion 969
15337028
Am J Physiol. 1997 Dec;273(6 Pt 2):H2931-6
9435634
Am J Physiol Heart Circ Physiol. 2004 Apr;286(4):H1273-80
14684373